It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Study of Combination Therapies in Relapsed and Refractory Multiple Myeloma

Clinical Trial Title: 
Clinical trial with combination therapies in relapsed and refractory multiple myeloma.
Clinical Trial Protocol ID: 
16030403
Clinical Trial Investigator Name: 
Agne Paner, MD
Clinical Trial Protocol Description: 

The goal of the trial is to assess efficacy and safety of pomalidomide in combination with nivolumab with or without elotzumuab in patients with relapsed multiple myeloma.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have relapsed or relapsed and refractory multiple myeloma.
  • Have received at least 2 prior lines of therapy, that includes proteasome inhibitor and immunomodulatory drug.

You will be excluded from the study if any of the following criteria apply to you:

  • Are refractory to pomalidomide or checkpoint inhibitors.
  • Have inadequate heart, kidney and/or liver function.
  • Have an active autoimmune disease.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-4685
Contact Name: 
Christine Deskovich, RN, BSN, OCN